Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Summary

The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.

Timeline

Start

2015-05

Primary completion

2019-12-10

Completion

2019-12-10

Drugs

Indications